"Armored" & TME Penetration TRuC-T Development Services

Q: How do you verify TME penetration?

We use ex vivo analysis of tumor tissues from xenograft models to quantify human T-cell infiltration. Our armored TRuC-T cells often show up to a 25-fold increase in intratumoral accumulation compared to standard constructs.

Online Inquiry

Background Service What We Can Offer Workflow Specialty Services Highlights FAQs Contact

Creative Biolabs provides "Armored" & TME Penetration TRuC-T Development Services to overcome major barriers in solid tumor immunotherapy, including poor T-cell persistence, therapeutic exhaustion, and limited infiltration into immunosuppressive tumor microenvironments. These services enable the development of highly potent and durable T-cell therapeutics through advanced T cell receptor fusion constructs integrated with membrane-bound cytokines and specialized tumor microenvironment modulating factors. By combining physiological TCR signaling with enhanced microenvironment adaptability, Creative Biolabs supports improved tumor penetration and sustained anti-tumor activity.

Introduction

Solid tumors present a formidable barrier due to their immunosuppressive microenvironment and physical density. Traditional CAR-T therapies often fail here due to limited signaling and exhaustion. TRuC-T technology addresses this by integrating antibody-based binders into the intact TCR complex, engaging all six subunits. By adding armors, we create a cell therapy that self-sustains and penetrates deep into the TME without the need for high-dose systemic cytokines.

Fig.1 Experimental Design for Cytotoxicity Assays of TRuCT Cells. (OA Literature) Fig.1 TRuC-T cell cytotoxicity assay design.¹

Service

Creative Biolabs provides a comprehensive, end-to-end solution for developing next-generation TRuC-T therapies specifically designed to thrive where conventional CAR-T cells fail. By leveraging the full signaling capacity of the TCR complex and "armoring" the cells with constitutive survival signals, we deliver a product capable of overcoming physical and chemical barriers within the TME.

Our services support clients from early design to functional validation, including targeted TRuC construct engineering for optimized antigen recognition and physiological signaling, armored T‑cell engineering to enhance resistance to immunosuppression, TME penetration optimization to improve tumor infiltration, and comprehensive in vitro and in vivo functional characterization and preclinical evaluation of cytotoxicity, persistence, immune activation, and tumor infiltration capacity.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Creative Biolabs supports comprehensive TRuC-T engineering and TME adaptation strategies, enabling flexible development of advanced cell therapy candidates.

TRuC Receptor Engineering Platform	Armored T-Cell Functional Enhancement Platform
Enables construction and optimization of fusion receptors linking antigen‑binding domains with TCR signaling components, supporting receptor design, construct optimization, and functional screening.	Integrates immune‑supportive elements to enhance cell persistence, survival, and anti‑tumor activity in immunosuppressive tumor microenvironments.
Tumor Microenvironment Adaptation Platform	Solid Tumor Functional Evaluation Platform
Improves T‑cell trafficking and tumor infiltration via chemokine guidance, stromal interaction modulation, and resistance to inhibitory signals.	Assesses anti‑tumor activity and immune function of TRuC‑T cells using tumor co‑culture and tumor microenvironment simulation models.

Our Workflow

Required Starting Materials: To launch the service, clients generally submit target antigen details and, where applicable, specified binder sequences. For projects lacking predefined binders, our in-house antibody discovery platforms can generate high-affinity candidates.

Workflow of 'Armored' & TME Penetration TRuC-T Development. (Creative Biolabs Original)

Specialty Services

"Armored" TRuC Construct Design

We design armored TRuC constructs with TME-shielding features to resist immunosuppression, enhance signaling strength, and improve persistence and antitumor efficacy in hostile tumor microenvironments.

T Cell Persistence & Exhaustion Modeling

Creative Biolabs provides T cell persistence and exhaustion modeling to evaluate durability, functional decline, and exhaustion markers, enabling optimization of TRuC-T performance and long-term therapeutic efficacy.

Tumor Homing & Migration Assay

We offer tumor homing and migration assays to assess TRuC-T trafficking, chemotaxis, and infiltration capabilities, supporting the development of cell therapies with improved tumor-targeting efficiency.

Core Benefits

Custom "Armor" Engineering: Integration of constitutive or inducible membrane-bound cytokines to enhance autonomous persistence and metabolic fitness.
TME-Modulating Enhancements: Co-expression of switch receptors or enzymes to degrade the extracellular matrix, facilitating deep TME penetration.
Advanced Binder Discovery: Access to high-affinity, fratricide-resistant scFv libraries designed for "cis-masking" of antigens.
Fratricide-Resistant Platforms: Specialized development for targets expressed on both tumors and activated T cells to ensure product viability during expansion.

FAQs

Q: What is the main advantage of TRuC-T over second-generation CAR-T?

A: TRuC-T cells utilize the entire TCR complex, which provides more physiological signaling and lower cytokine release than CARs, reducing the risk of tonic signaling and over-activation.

Q: Can you develop TRuC-T cells for targets that cause fratricide?

A: Yes. For targets like CD70, we select specific binders that exhibit "cis-masking," where the TRuC occupies the antigen on the T cell's own surface, protecting it from being killed by its neighbors.

Q: How do you verify TME penetration?

A: We use ex vivo analysis of tumor tissues from xenograft models to quantify human T-cell infiltration. Our armored TRuC-T cells often show up to a 25-fold increase in intratumoral accumulation compared to standard constructs.

Partner with Us

Creative Biolabs stands at the forefront of TCR-based engineering. Unlike competitors who rely on standard CAR-T designs, our TRuC-T platform utilizes the entire physiological signaling machinery of the T cell, resulting in lower cytokine release and reduced risk of Cytokine Release Syndrome (CRS). Our "armored" variants provide the necessary metabolic fuel to survive and infiltrate cold, immunosuppressive tumors. To obtain detailed information and discuss your specific project needs with our scientists, feel free to contact our team for further communication and project consultation.

Reference

Webb, Lindsay et al. "Membrane-bound IL-15 co-expression powers a potent and persistent CD70-targeted TRuC T-cell therapy." Frontiers in immunology vol. 16 1609658. 30 May. 2025. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2025.1609658

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.